This company listing is no longer active
Clover Biopharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Clover Biopharmaceuticals's earnings have been declining at an average annual rate of -16.2%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-16.2%
Earnings growth rate
-13.6%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | n/a |
| Return on equity | -2,329.7% |
| Net Margin | -258,830.4% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Clover Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -665 | 317 | 996 |
| 31 Mar 23 | 0 | -1,559 | 364 | 1,230 |
| 31 Dec 22 | 0 | -2,452 | 410 | 1,465 |
| 30 Sep 22 | 0 | -4,145 | 428 | 1,757 |
| 30 Jun 22 | 0 | -5,838 | 446 | 2,048 |
| 31 Mar 22 | 0 | -5,927 | 396 | 1,937 |
| 31 Dec 21 | 0 | -6,016 | 346 | 1,826 |
| 31 Dec 20 | 0 | -913 | 76 | 228 |
Quality Earnings: 2197 is currently unprofitable.
Growing Profit Margin: 2197 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2197 is unprofitable, and losses have increased over the past 5 years at a rate of 16.2% per year.
Accelerating Growth: Unable to compare 2197's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2197 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: 2197 has a negative Return on Equity (-2329.68%), as it is currently unprofitable.